‘We need to do more’: Merck CEO Rob Davis highlights M&A, deals strategy ahead of ’28 Keytruda patent cliff

With megablockbuster Keytruda’s patent cliff looming in 2028, Merck has made some bold M&A moves in an attempt to find its next big moneymaker, including last year’s $11.5 billion acquisition of Acceleron. According to CEO Robert Davis, there’s plenty more of that coming in 2022.

The chief executive highlighted the...

Click to view original post